Haleon (NYSE:HLN) Stock Moved Down to Strong Sell by Zacks Research

Key Points

• Zacks Research downgraded Haleon from “hold” to “strong sell,” although broader analyst sentiment remains “Moderate Buy” with an average price target of $4.90.
• Haleon shares opened at $10.29, compared with a 52-week range of $8.65 to $11.28; the company has a $45.30 billion market capitalization and trades at a P/E ratio of 26.37.
• Institutional ownership stands at 6.67%, with several major investors—including Mondrian Investment Partners, Arrowstreet Capital and Bank of America—recently increasing or initiating positions.

Haleon (NYSE:HLN - Get Free Report) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Thursday, Zacks reports.

Several other research analysts have also weighed in on the stock. Royal Bank Of Canada restated a "sector perform" rating on shares of Haleon in a research report on Tuesday, August 11th. Jefferies Financial Group reissued a "buy" rating on shares of Haleon in a research note on Wednesday, September 23rd. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a report on Friday, September 25th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Haleon in a research note on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and an average price target of $4.90.

Haleon Stock Performance

NYSE:HLN opened at $10.29 on Thursday. The firm's fifty day simple moving average is $9.56 and its 200-day simple moving average is $9.51. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The stock has a market cap of $45.30 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.34 and a beta of 0.14. Haleon has a fifty-two week low of $8.65 and a fifty-two week high of $11.28.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HLN. Mondrian Investment Partners LTD purchased a new stake in Haleon in the 3rd quarter worth approximately $158,737,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Haleon by 82.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company's stock worth $146,892,000 after purchasing an additional 6,647,329 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Haleon by 27,393.7% during the 1st quarter. Principal Financial Group Inc. now owns 2,803,530 shares of the company's stock worth $28,063,000 after purchasing an additional 2,793,333 shares during the period. Bank of America Corp DE boosted its holdings in shares of Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock worth $109,452,000 after purchasing an additional 1,586,230 shares during the last quarter. Finally, JTC Employer Solutions Trustee Ltd boosted its holdings in shares of Haleon by 470.2% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 1,610,721 shares of the company's stock worth $16,115,000 after purchasing an additional 1,328,217 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

About Haleon

Haleon plc NYSE: HLN is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company's products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.